We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Technology Pulls Elusive COVID-19 Marker from Blood to Better Measure Disease Severity

By LabMedica International staff writers
Posted on 02 Nov 2020
Researchers have created a new technology that can detect an elusive protein bio-marker from human blood to measure the severity of COVID-19.

McMaster University (Hamilton, ON, Canada) in collaboration with SQI Diagnostics, Inc. More...
(Toronto, ON, Canada) have created a surface that repels every other element of human blood except critical cytokine biomarkers like Interleukin-6 (IL-6), enabling timely and clear detection of critical "cytokine storm" progress of COVID-19 in individual patients. The same bio-sensing technology can also be used to measure disease severity in patients with influenza or other acute respiratory distress conditions, as well as other infectious and non-infectious diseases, including some cancers.

The innovative technology is a proprietary surface coating that repels every component of blood and other complex fluids, while containing microscopic molecules that attract IL-6, making it possible to detect and measure IL-6 with unprecedented accuracy and sensitivity, at concentrations as low as 0.5 picograms per mL - or one half of one trillionth of a gram per mL. SQI and McMaster are working on a process to adapt the technology into SQI's existing testing platforms, with the goal of moving it into use as soon as possible.

"There are so many possibilities for these smart surfaces. We can create them to repel everything, or we can design them to interact in many beneficial ways," said Dr. Tohid Didar, Professor of Mechanical Engineering at McMaster. "In this application, we have designed it to detect only the one bio-marker IL-6, and this allows us to separate it from everything else in a very complex environment, enabling clear quantitative detection of its presence."

"Our collaboration with McMaster University has led to an innovative pathway to a potentially more efficient and effective manufacturing design that strengthens SQI's ability to provide extremely accurate diagnostics for testing in the COVID-19 pandemic, as well as other critical conditions," added Dr. Eric Brouwer, Chief Scientific Officer of SQI Diagnostics.

Related Links:
SQI Diagnostics, Inc.
McMaster University



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Portable Electronic Pipette
Mini 96
Rapid Molecular Testing Device
FlashDetect Flash10
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.